Bayer HealthCare has obtained approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its Nexavar (sorafenib) for treatment of patients with unresectable differentiated thyroid carcinoma.

⋮

0

← $

..going to article 599

X Mark channel Not-Safe-For-Work? cancel confirm NSFW Votes: (0 votes)

X Are you the publisher? Claim or contact us about this channel.

X No ratings yet.

X Search